Addinex Technologies' Success in Decreasing Opioid Refills and Increasing Disposal of Excess Pills After Surgery Validated in Clinical Study
Results of study by Columbia University Irving Medical Center
published in "Cancer", a peer-reviewed journal of the American Cancer Society
NEW YORK, NY, July 12, 2022 – The final results of an opioid misuse prevention study by Columbia University Irving Medical Center using the patented digital medication dispensing system developed by Addinex Technologies, Inc. were published in the peer-reviewed journal, Cancer.
Study results of 30 patients undergoing major cancer-related surgery showed high rates of excess medication disposal, low prescription refill rates, a greater feeling of safety, and a strong positive experience by study participants.
43% of study patients underwent open total abdominal hysterectomy, 33% underwent mastectomy and 23% underwent cutaneous tumor resections
567 opioid pills were prescribed (average 18.9) and only 170 (30%) were used
84% of excess pills were returned for proper disposal versus no more than 9% in prior studies
Only 63% of patients used any opioids and only two patients obtained a refill
Over half of patients felt safer using the Addinex system
74% felt that the benefits of the Addinex system justified its use over a typical pill bottle
Study participants prescribed opioids after surgery used Addinex’s low-cost password-protected medication dispenser which limits availability to no more than their prescription allows (e.g., one pill every four hours). The associated app monitored pain levels and provided physician-driven advice based on each patient’s progress. When pain levels subsided, patients were prompted to dispose of their excess pills and dispenser in a provided DEA-approved disposal mailer.
“Initial opioid exposures often occur post-operatively, and 10% of opioid-naïve patients undergoing surgery for cancer subsequently become long-term opioid users.[i] 70% of opioids prescribed post-operatively go unused, but only 9% of leftover pills are disposed of appropriately,[ii] increasing the risk of unintended use,” according to Jacob Cogan, M.D., Hematology/Oncology Fellow at Columbia University Irving Medical Center during this study and ASCO Merit Award recipient for his work on this study.
Dawn Hershman, M.D., M.S., principal study investigator and the Director of Breast Oncology and co-leader of the Cancer Population Science program at the Herbert Irving Comprehensive Cancer Center at Columbia University stated “Our early findings suggest that utilization of an inexpensive, password-protected, pill-dispensing system, like the one developed by Addinex to assist with opioid dispensing, education and excess pill disposal, is feasible with high rate of success. This solution appears to be an effective strategy to protect patients and reduce opioid diversion.”
“Patients retain over three billion excess opioid pills in a year[iii] and over half of illicit use comes from friends and relatives.[iv] With 80% of heroin users having started on prescription opioids,[v] a solution is needed to reduce the number of opioids pills prescribed, educate patients on their usage in real time, and make it easy to dispose of excess pills’” stated Jay Schiff, Co-Founder and CEO of Addinex Technologies, Inc. “Our medication dispensing system provides a cost-effective, multi-pronged solution for opioids and other misused medications like buprenorphine, methadone, stimulants, and sedatives.”
About Addinex Technologies, Inc.
Addinex Technologies is a cutting-edge developer of low-cost medication dispensing systems targeting misused prescription drugs. Addinex’s patented low-cost mechanical dispenser regulates usage based on each patient’s unique prescription, assists doctors with prescribing based on usage data by similar patients, provides education and real-time progress feedback to patients and their doctors, and incorporates a DEA-approved mailer for easy excess pill disposal. For more information, visit Addinex at www.addinex.com.
Jay Schiff, Co-Founder and CEO
Addinex Technologies, Inc.
[i] Jay Soong-Jin Lee, Hsou Mei Hu, Anthony L. Edelman, Chad M. Brummett, Michael J. Englesbe, Jennifer F. Waljee, Jeffrey B. Smerage, Jennifer J. Griggs, Hari Nathan, Jacqueline S. Jeruss, and Lesly A. Dossett. New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. Journal of Clinical Oncology 2017 35:36, 4042-4049
[ii] Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review. JAMA Surg. 2017;152(11):1066-1071. doi:10.1001/jamasurg.2017.0831
[iii] UNITED STATES FOR NON-DEPENDENCE, An Analysis of the Impact of Opioid Overprescribing in America, September 26, 2017, QuintilesIMS Institute (now IQVIA)
[iv] Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
[v] Muhuri PK, Davies MC. Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States. CBHSQ Data Review, SAMHSA., 2013